Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Line Clear all
Completed Phase 1 Interventional

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT00712855
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
mapatumumab, sorafenib
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 31, 2026, 2:49 AM EDT
Completed No phase listed Observational

Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients

NCT03674216
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Jonathan B. Zuckerman
Other
Eligibility
6 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Phase 1Phase 2 Interventional

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

NCT01271920
View directory record Official record
Conditions
Advanced HER2-positive Breast Cancer
Interventions
AUY922, Trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 31, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005
View directory record Official record
Conditions
Thrombosis
Interventions
alteplase
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 66 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 31, 2026, 2:49 AM EDT
Terminated Not applicable Interventional

Landmark vs. Ultrasound Guided SCVC in the ED

NCT01914705
View directory record Official record
Conditions
Hypotensive
Interventions
Landmark Procedure, Ultrasound Guided Procedure
Procedure
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Phase 3 Interventional

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

NCT00063141
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, Irinotecan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
116
States / cities
Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2010 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Not applicable Interventional Results available

Pediatric Catheter-related Thrombosis Imaging Study

NCT01137578
View directory record Official record
Conditions
Thrombosis
Interventions
Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast
Procedure · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 18 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Aurora, Colorado • Kansas City, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 31, 2026, 2:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ED Residents MBP During CVC Placement: Sim Lab Based Training

NCT00791583
View directory record Official record
Conditions
Nosocomial Infections
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 31, 2026, 2:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097
View directory record Official record
Conditions
Relapsed or Refractory Follicular Lymphoma
Interventions
Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly

NCT02151149
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Large Cell, Lung Neoplasm
Interventions
nab-paclitaxel, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
70 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
55
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 31, 2026, 2:49 AM EDT
Recruiting Phase 3 Interventional

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

NCT07465718
View directory record Official record
Conditions
Wilson's Disease
Interventions
TETA 4HCl formulation, D-Penicillamine
Drug
Lead sponsor
Orphalan
Industry
Eligibility
8 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Denver, Colorado • New Haven, Connecticut • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 2:49 AM EDT
Not listed Phase 1Phase 2 Interventional

Evaluating Central Line Hub Contamination Using a Novel Capping Device

NCT01301300
View directory record Official record
Conditions
Catheter-related Bloodstream Infection Due to Central Venous Catheter
Interventions
Disinfecting Cap
Device
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Evanston, Illinois • Glenview, Illinois • Highland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 31, 2026, 2:49 AM EDT
Recruiting Phase 3 Interventional

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 2:49 AM EDT
Terminated Not applicable Interventional

Can Ultrasound be Used to Verify CVC Position and to Exclude Pneumothorax?

NCT00388375
View directory record Official record
Conditions
Catheterization, Central Venous
Interventions
Ultrasound
Procedure
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 31, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

NCT01195727
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orange, California • New Brunswick, New Jersey • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Not applicable Interventional

Superficial Cervical Plexus Block for IJCL Pain Management

NCT05252832
View directory record Official record
Conditions
Superficial Cervical Plexus Block, Pain
Interventions
Superficial Cervical Plexus Block, Local Infiltrate
Procedure
Lead sponsor
Cleveland Clinic Akron General
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 2:49 AM EDT
Terminated Not applicable Interventional Results available

The Pristine Post-Market Study

NCT05228132
View directory record Official record
Conditions
Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure, Central Venous Catheter Related Bloodstream Infection, End Stage Renal Disease
Interventions
Pristine™ Long-Term Hemodialysis Catheter
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
6
States / cities
Dothan, Alabama • New Haven, Connecticut • Shreveport, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 31, 2026, 2:49 AM EDT
Active, not recruiting Phase 2 Interventional

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

NCT06894511
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
AAA617, ARPI: Abiraterone, ARPI: Enzalutamide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 2:49 AM EDT
Terminated Phase 3 Interventional

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

NCT01493505
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Interventions
AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
173
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 142 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 31, 2026, 2:49 AM EDT
Completed No phase listed Observational

Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

NCT01988766
View directory record Official record
Conditions
Thrombosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 31, 2026, 2:49 AM EDT
Active, not recruiting Phase 3 Interventional

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797
View directory record Official record
Conditions
Relapsed or Refractory Large B-cell Lymphoma
Interventions
KITE-753, Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
21
States / cities
Goodyear, Arizona • Duarte, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 2:49 AM EDT
Completed Phase 3 Interventional

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

NCT00752258
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Mentor Purified Toxin Botulinum Toxin Type A
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 31, 2026, 2:49 AM EDT